In conclusion, the role of plasmatic EVs in the progression of oncological diseases, as well as their therapeutic potential [70], together with the specificity of neoplastic transformation indicators such as KRT19 or diverse CAFs markers, leads us to consider that the development of a non-invasive cancer diagnosis system using a combination of epithelial and mesenchymal markers could be a promising approach in the diagnosis of several neoplastic processes. This evidence concerns the gene KRT19 and cancer.